Research

The purpose of this study is to establish a cohort of asthmatic patients who have exacerbated during the last year, in order for us to phenotype and thus characterize the nature of their asthma at the point of an exacerbation.

Once subjects have been recruited to the study, they will be extensively phenotyped at baseline including spirometry, FeNO and induced sputum.

At the point of a perceived exacerbation participants will contact a dedicated study telephone number and will be invited to the Nottingham Asthma Center to undergo assessment into the aetiology of their exacerbation.

Treatment for a suspected exacerbation will be provided in the form of a prescription of prednisolone if clinically indicated. Patients will be followed up 7 days after to assess for resolution of their symptoms.

Patients will be in the study for 3 years and will have annual visits to assess their asthma.

Data on reliever medication use leading up to an exacerbation will be collected from those participants who use the devices. This will be analysed retrospectively to investigate the utility of this data, in the prediction of the development of an exacerbation.

Symptoms due to low sugar levels (hypoglycaemia) a few hours after eating is a common problem after weight-loss surgery which can be distressing. Currently there is no good treatment available for this problem. The underlying cause is unclear, however after weight loss surgery, people with hypoglycaemia after a meal produce more than the necessary amounts of insulin.

Canagliflozin, a treatment for type 2 diabetes, has been shown to reduce insulin production after a meal in patients without diabetes. Additionally, the lowest glucose levels 2 to 3 hours after eating are slightly increased with the use of canagliflozin in patients without diabetes. If this is also the case after weight-loss surgery, then canagliflozin could be a treatment option for hypoglycaemia after eating due to weight-loss surgery.

Fractional exhaled nitric oxide (FeNO) is a simple, non-invasive breath test, which provides objective evidence of steroid-responsive eosinophilic airway inflammation. The National Institute for Health and Care Excellence (NICE) already recommends that clinicians should use FeNO to help them diagnose asthma more accurately. However, NICE has also highlighted the need for more robust evidence to guide use of FeNO in monitoring asthma treatment to prevent acute exacerbations. 

This research activity seeks to determine the impact of type 2 diabetes (T2DM) on liver fat quality/composition in individuals with non-alcoholic fatty liver disease (NAFLD) and to characterise changes in liver fat quality/composition in response to a supervised exercise training programme.

MyMelanoma is a partnership between people who have been affected by melanoma, clinicians and researchers to form the largest melanoma research study in the world.

MyMelanoma is designed to answer the most important unanswered questions in melanoma research, and is open to anyone who has ever been diagnosed with a melanoma of the skin, of the mucosal surfaces (e.g. nose, genitals) or under the nails.

Will you join us?
To sign up to be part of MyMelanoma or if you have any questions for us, please visit our website: www.mymelanomastudy.org

This practice contributes pseudonymised data for national research and surveillance. This data enables continuous monitoring of infections and diseases and is used in ethically approved research. This is the main source of information for the Health Security Agency and helps to predict and manage outbreaks and pandemics.

The overall purpose of this study is to determine the clinical and cost-effectiveness of allopurinol based treat-to-target (T2T) urate lowering treatment (ULT) in people with recurrent gout flares compared to usual GP care.